Cellegy issued patent covering use of potassium channel openers to treat anorectal disorders.
Potassium channel openers help smooth muscle relaxation and, therefore, are anticipated to provide useful medical options in treating anorectal disorders. Data obtained from in vivo experiments demonstrated effective internal anal sphincter relaxation with administration of various potassium channel openers. These agents are expected to compliment Cellegesic's (nitroglycerin ointment) effect on smooth muscle relaxation.
Dr. Vivien Mak, Vice President of Research at Cellegy, commented, "Over the past two weeks, Cellegy has been issued two important United States patents (covering the use of PDE inhibitors and potassium channel openers) that result from our ongoing efforts to develop products for the treatment of fissures and hemorrhoids. Such products are expected to deepen our Cellegesic product line through the development of new dosage forms, line extensions and product improvements in order to maximize the commercial potential of Cellegy's investment in this greatly underserved therapeutic area. Our patent portfolio in this field has been significantly strengthened by the two recently issued patents."
Cellegy is a specialty biopharmaceutical company focused on the areas of gastroenterology, sexual dysfunction in males and females, and various women's health conditions.
Cellegy has a significant pipeline of late stage products. Apart from Cellegesic, which is the subject of ongoing discussions with the FDA regarding requirements for marketing approval in the United States, the company recently announced that it has filed an NDA (New Drug Application) on its patented product Tostrex (testosterone gel), for the treatment of male hypogonadism. Another product in Cellegy's pipeline, Tostrelle, a transdermal testosterone gel for the treatment of female sexual dysfunction entered into Phase II/III clinical testing during the first quarter of 2002.
Additional pipeline products include nitric oxide donors for the treatment of dyspareunia (a form of sexual dysfunction) in females, Raynaud's Disease, Restless Leg Syndrome, and prostate cancer, as well as products for the treatment of male erectile dysfunction. Cellegy is currently exploring various partnering opportunities for these patent protected product candidates in the United States and international markets.
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||Jun 1, 2002|
|Previous Article:||Endovasc files patent application for angiogenesis stent.|
|Next Article:||Introgen's mda-7 gene therapeutic receives patent.|